The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Herb-drug interaction between baicalin and rosuvastatin

    Baicalin (Chinese skullcap) comes from Scutellaria baicalensis Georgi. This anti-inflammatory herbal is used in traditional Chinese medicine to treat cancer, liver disease, allergies, skin conditions, and epilepsy. Rosuvastatin (Crestor) is a member of the stain class of drugs used to lower LDL (bad) cholesterol.

    First, the details from a study by researchers at Central South University in the People’s Republic of China

    • 18 healthy volunteers received each treatment.
    • Rosuvastatin (20 mg by mouth) plus placebo or 50-mg baicalin tablets (3 times daily for 14 days).
    • The ability to absorb rosuvastatin into the blood was determined after each treatment.

    And, the results.

    • After baicalin treatment, the ability of the body to absorb rosuvastatin (bioavailability) decreased significantly.

    The bottom line?
    Certain people are more susceptible to this interaction. Those with the organic anion-transporting polypeptide 1B1 (OATP1B1) in their intestines experienced the greatest decrease in rosuvastatin bioavailability. Those with OATP1B1 1b/1b or 1b/15 experienced significantly less of a decrease in bioavailability.

    From a practical perspective, your healthcare provider is unlikely to test for this enzyme. Therefore, all patients taking Chinese skullcap should make this information known before starting rosuvastatin treatment.

    I do not know if this interaction occurs with other statins, nor how much the interaction affects the LDL cholesterol response to rosuvastatin.

    9/13/07 15:14 JR

    Leave a Comment

    You must be logged in to post a comment.